Biologics Transition 'Dead Zone' Could Be Eliminated Under US Senate Bill

 
• By Derrick Gingery

Discussion draft includes provision requiring completion of assessments of transitioning NDA applications filed by 23 September, even if review lasts beyond the official 2020 transition date.

United States Capitol Building in Washington DC USA
Stakeholder comments on the Senate drug pricing discussion draft are due to the Health, Education, Labor and Pensions Committee by 5 June. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics